Divi's Labs gets US FDA Form 483 for Vizag API plant

By Gareth Macdonald contact

- Last updated on GMT

Divi's Unit-2 facility in Vizag (source Divi's website)
Divi's Unit-2 facility in Vizag (source Divi's website)

Related tags: Food and drug administration, Fda

The US FDA has found more problems at a Divi’s Laboratories Limited API facility that was banned from shipping to the US earlier this year.

The facility in Visakhapatnam, India – known as Unit-2 – was issued with a Form 483 detailing six problems identified by US Food and Drug Administration (FDA) inspectors who audited the site between September 11 and 13.

In a Bombay Stock Exchange filing last week, Divi’s told​ investors the observations are "procedural​" and that it will “be responding to these within the stipulated time​.”

It explained that “The inspection was for full cGMP and verification of all Corrective Actions proposed against the previous inspection observations” ​adding that “all previous observations have been confirmed and resolved​.”

Divi’s did not specify to which “previous inspection observations” ​it is referring or respond when we asked for more information.

Compliance history

The Unit-2 facility was landed with a US import ban in March​. At the time, Divi’s said the alert had been issued under clauses 66-40 and 99-32 of US Food and Drug Administration (FDA) regulations.

66-40​ import alert is issued when “inspection has revealed that a firm is not operating in conformity with current good manufacturing practices (GMP's).”

99-32​ alert is issued to firms that have either refused to “permit inspection of a foreign facility or provide reasonable access to FDA's inspectional personnel​.”

In July​, Divi’s said the US regulator was poised to lift the 99-32 import alert. The firm is no longer listed on the 99-32​ alert page on the FDA’s website but is still liste on the 66-40​ page.

European audits

The US FDA is not the only regulator to have visited the site. 

In August, Divi’s said inspectors from Ireland’s HPRA and Slovenia’s JAZMP who audited the site the previous month had made “no critical observations​.”

Related news

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 07-Dec-2021 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

LACTIUM®: dairy bioactive to soothe your pet

LACTIUM®: dairy bioactive to soothe your pet

Ingredia | 12-Oct-2021 | Infographic

Lactium® gives you the chance to better meet your pet’s needs for a more harmonious life together. Lactium® acts on the brain and has no side-effects,...

Related suppliers

Follow us

Products

View more

Webinars